BHCM
ACRS icon

Boulder Hill Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Boulder Hill Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,200
Closed -$163K – 138
2021
Q4 		$163K Buy
+11,200
New +$170K 0.16% 144

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Boulder Hill Capital Management's ACRS Position: Q1 2022 in Review

Boulder Hill Capital Management sold out of Aclaris Therapeutics (ACRS) in Q1 2022, closing a stake of 11,200 shares — an estimated $163K sold.

Boulder Hill Capital Management first reported a position in ACRS in Q4 2021 and held it in 1 quarter. The position peaked at $163K in Q4 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

  • Boulder Hill Capital Management reported no remaining Aclaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Boulder Hill Capital Management sold 11,200 Aclaris Therapeutics shares in Q1 2022, an estimated $163K.
  • Boulder Hill Capital Management first reported a position in Aclaris Therapeutics in Q4 2021 and held it in 1 quarter.
  • Boulder Hill Capital Management's Aclaris Therapeutics position peaked at $163K in Q4 2021.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on Boulder Hill Capital Management's 13F filing for Q1 2022, filed 12 May 2022.